Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy†

Javor, Edward D., Ghany, Marc G., Cochran, Elaine K., Oral, Elif Arioglu, DePaoli, Alex M., Premkumar, Ahalya, Kleiner, David E., Gorden, Phillip·2005·Hepatology
DOI 10.1002/hep.20672

Cited by (228)

Items 101–200 of 228

  1. Clinical Spectrum of LMNA-Associated Type 2 Familial Partial Lipodystrophy: A Systematic Review
    Antía Fernández‐Pombo, Everardo Josué Díaz‐López, Ana I. Castro, Sofía Sánchez‐Iglesias, Silvia Cobelo-Gómez, Teresa Prado‐Moraña, David Araújo‐Vilar · 2023 · Cells
  2. A Myriad of Pathways to NASH
    Soledad Larrain, Mary Eugenia Rinella · 2012 · Clinics in Liver Disease
  3. Alterations in Lipids and Adipocyte Hormones in Female-to-Male Transsexuals
    Prakash Chandra, Sukhdeep S. Basra, Tai C. Chen, Vin Tangpricha · 2010 · International Journal of Endocrinology
  4. Drug targeting of leptin resistance
    Anna Natalizia Santoro, Giuseppina Mattace Raso, Rosaria Meli · 2015 · Life Sciences
  5. Effects of Metreleptin on Patient Outcomes and Quality of Life in Generalized and Partial Lipodystrophy
    Keziah Cook, Kelly N. Adamski, Dumingu Aparna Gomes, Edward Tuttle, Henner Kalden, Elaine K. Cochran, Rebecca J. Brown · 2021 · Journal of the Endocrine Society
  6. Leptin and liver tissue repair: Do rodent models provide the answers?
    Fabio Marra · 2006 · Journal of Hepatology
  7. Update on Therapeutic Options in Lipodystrophy
    Barış Akıncı, Rasimcan Meral, Elif A Oral · 2018 · Current Diabetes Reports
  8. Pro‐inflammatory signalling and gut‐liver axis in non‐alcoholic and alcoholic steatohepatitis: Differences and similarities along the path
    Trenton Glaser, Leonardo Baiocchi, Tianhao Zhou, Heather Francis, Ilaria Lenci, Giuseppe B. Grassi, Lindsey Leann Kennedy, Suthat Liangpunsakul, Shannon S. Glaser, Gianfranco D. Alpini et al. · 2020 · Journal of Cellular and Molecular Medicine
  9. Serum Leptin in Patients with Alcoholic Liver Disease
    Sylvie Naveau, Gabriel Perlemuter, Muriel Chaillet, Bruno Raynard, Axel Balian, Fabienne Beuzen, Alain Portier, Pierre Galanaud, Dominique Émilie, Jean‐Claude Chaput · 2006 · Alcoholism Clinical and Experimental Research
  10. Time to transition from a negative nomenclature describing what NAFLD is not, to a novel, pathophysiology-based, umbrella classification of fatty liver disease (FLD)
    Laura Valenzuela‐Vallejo, Christos Socrates Mantzoros · 2022 · Metabolism
  11. Non‐Alcoholic Fatty Liver and Non‐Alcoholic Steatohepatitis
    Geoffrey C. Farrell · 2007
  12. Pediatric non-alcoholic fatty liver disease: current perspectives on diagnosis and management
    Anna Di Sessa, Grazia Cirillo, Stefano Guarino · 2019 · Pediatric Health Medicine and Therapeutics
  13. Increased proinflammatory cytokine production in adipose tissue of obese patients with chronic kidney disease
    Vladimı́r Teplan, F Vyhnánek, R Gürlich, Martin Haluzı́k, Jaroslav Ráček, Ivana Vyhnankova, M Štollová, Vladimı́r Teplan · 2010 · Wiener klinische Wochenschrift
  14. New advances in the treatment of generalized lipodystrophy: role of metreleptin
    Gilberto Paz-Filho, Alexander J. Rodríguez, Claudio Alberto Mastronardi · 2015 · Therapeutics and Clinical Risk Management
  15. Exercise training decreases plasma leptin levels and the expression of hepatic leptin receptor-a, -b, and, -e in rats
    Siham Yasari, Donghao Wang, Denis Prud’homme, Marek Jankowski, Jolanta Gutkowska, Jean-Marc Lavoie · 2008 · Molecular and Cellular Biochemistry
  16. Chinese Medicinal Herbs Targeting the Gut–Liver Axis and Adipose Tissue–Liver Axis for Non-Alcoholic Fatty Liver Disease Treatments: The Ancient Wisdom and Modern Science
    Shuwei Zhang, Yui-Tung Wong, Ka-Yu Tang, Hiu Yee Kwan, Tao Su · 2020 · Frontiers in Endocrinology
  17. Metreleptin therapy for nonalcoholic steatohepatitis: Open-label therapy interventions in two different clinical settings
    Barış Akıncı, Angela R. Subauste, Nevin Ajluni, Nazanene Helen Esfandiari, Rasimcan Meral, Adam Neidert, Akin Eraslan, RITA P. HENCH, Diana Rus, Barbara J. McKenna et al. · 2021 · Med
  18. Metreleptin and generalized lipodystrophy and evolving therapeutic perspectives
    Tchang, Beverly G, Shukla, Alpana P, Aronne, Louis J · 2015 · Expert Opinion on Biological Therapy
  19. Mouse Models of Liver Parenchyma Injuries and Regeneration
    Yuan Du, Wencheng Zhang, Hua Qiu, Canjun Xiao, Jun Shi, Lola McAdams Reid, Zhiying He · 2022 · Frontiers in Cell and Developmental Biology
  20. Regional Anthropometric Measures and Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
    Ayako Suzuki, Manal F. Abdelmalek, Aynur Ünalp–Arida, Katherine P. Yates, Arun Jayant Sanyal, Cynthia D. Guy, Anna Mae Diehl · 2010 · Clinical Gastroenterology and Hepatology
  21. Therapeutic use of recombinant methionyl human leptin
    Camille Vatier, Jean–François Gautier, Corinne Vigouroux · 2012 · Biochimie
  22. Administration of small-molecule guanabenz acetate attenuates fatty liver and hyperglycemia associated with obesity
    Satoshi Yoshino, Yusaku Iwasaki, Shunichi Matsumoto, Tetsurou Satoh, Atsushi Ozawa, Eijiro Yamada, Satoru Kakizaki, Juan Alejandro Oliva Trejo, Yasuo Uchiyama, Masanobu Yamada et al. · 2020 · Scientific Reports
  23. Effect of Leptin Therapy on Survival in Generalized and Partial Lipodystrophy: A Matched Cohort Analysis
    Keziah Cook, Omer Ali, Barış Akıncı, Maria Cristina Foss‐Freitas, Renan Magalhães Montenegro, Virgínia Oliveira Fernandes, Deepshekhar Gupta, Kai-Jye Lou, Edward Tuttle, Elif A Oral et al. · 2021 · The Journal of Clinical Endocrinology & Metabolism
  24. A rapid action plan to improve diagnosis and management of lipodystrophy syndromes
    Lindsay T. Fourman, Josivan Gomes Lima, Vinaya Simha, Marco Cappa, Saif Al-Yaarubi, Renan Magalhães Montenegro, Barış Akıncı, Ferruccio Santini · 2024 · Frontiers in Endocrinology
  25. The liver and the kidney: two critical organs influencing the atherothrombotic risk in metabolic syndrome
    Federico Carbone, François Mach, Roberto Pontremoli, Francesca Chiara Viazzi, Fabrizio Montecucco · 2013 · Thrombosis and Haemostasis
  26. Cholic acid for hepatic steatosis in patients with lipodystrophy: a randomized, controlled trial
    Zahid Ahmad, Lalitha Subramanyam, Lidia S. Szczepaniak, Vinaya Simha, BEVERLEY A. ADAMS-HUET, Abhimanyu Garg · 2013 · European Journal of Endocrinology
  27. Effects of Leptin Replacement Therapy on Pancreatic β-Cell Function in Patients With Lipodystrophy
    Ranganath Muniyappa, Rebecca J. Brown, Andrea Mari, Jalaja Joseph, Mary A. Warren, Elaine K. Cochran, Monica C. Skarulis, Phillip Görden · 2014 · Diabetes Care
  28. Whither Recombinant Human Leptin Treatment for HIV-Associated Lipoatrophy and the Metabolic Syndrome?
    Christos Socrates Mantzoros · 2009 · The Journal of Clinical Endocrinology & Metabolism
  29. Leptin in Relation to the Lipodystrophy-Associated Metabolic Syndrome
    Christos Socrates Mantzoros · 2012 · Diabetes & Metabolism Journal
  30. Consequences of Stopping and Restarting Leptin in an Adolescent with Lipodystrophy
    F. Kamran, K.I. Rother, Elaine K. Cochran, Elika Safar Zadeh, Phillip Görden, R.J. Brown · 2012 · Hormone Research in Paediatrics
  31. Clinical Spectrum and Therapy of Non-Alcoholic Steatohepatitis
    Christopher Paul Day · 2012 · Digestive Diseases
  32. Plasma adiponectin—an independent indicator of liver fat accumulation
    Pauliina Pisto, Olavi H. Ukkola, Merja Santaniemi, Y. Antero Kesäniemi · 2011 · Metabolism
  33. Laminopathies’ Treatments Systematic Review: A Contribution Towards a ‘Treatabolome’
    António Atalaia, Rabah Ben Yaou, Karim Wahbi, Annachiara De Sandre‐Giovannoli, Corinne Vigouroux, Gisèle Bonne · 2021 · Journal of Neuromuscular Diseases
  34. Impact of leptin deficiency compared with neuronal-specific leptin receptor deletion on cardiometabolic regulation
    Jussara Marcia do Carmo, Alexandre A. da Silva, Fábio Nelson Gava, Sydney P. Moak, Xuemei Dai, John Edward Hall · 2019 · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology
  35. Etiological investigations in apparent type 2 diabetes: when to search for lamin A/C mutations?
    Bruno Donadille, Olivier Lascols, Jacqueline Capeau, Corinne Vigouroux · 2005 · Diabetes & Metabolism
  36. Practice guideline for lipodystrophy syndromes—clinically important diseases of the Japan Endocrine Society (JES)
    Tomohiro Tanaka, Toru Kusakabe, Ken Ebihara, Megumi Aizawa-Abe, Daisuke Aotani, Tohru Yorifuji, Mari Satoh, Yoshihiro Ogawa, Kazuwa Nakao · 2021 · Endocrine Journal
  37. Leptin in congenital or HIV-associated lipodystrophy and metabolic syndrome: A need for more mechanistic studies and large, randomized, placebo-controlled trials
    Joo‐Pin Foo, Christos Socrates Mantzoros · 2012 · Metabolism
  38. Leptin replacement therapy for the treatment of non-HAART associated lipodystrophy syndromes: a meta-analysis into the effects of leptin on metabolic and hepatic endpoints
    Alexander J. Rodríguez, Teresa M. Neeman, Aaron G. Giles, Claudio Alberto Mastronardi, Gilberto Da Paz Filho · 2014 · Arquivos Brasileiros de Endocrinologia & Metabologia
  39. Leptin in the Liver: A Toxic or Beneficial Mix?
    Marc L. Reitman · 2012 · Cell Metabolism
  40. Liver Failure and Liver Disease
    Elwyn Elias · 2006 · Hepatology
  41. Diagnosis and management of lipodystrophy: a practical update
    Anna J. Stears, Catherine Hames · 2014 · Clinical Lipidology
  42. Molecular pathways involved in the improvement of non-alcoholic fatty liver disease
    Gilberto Paz-Filho, Claudio Alberto Mastronardi, Brian John Parker · 2013 · Journal of Molecular Endocrinology
  43. Obestatin protects and reverses nonalcoholic fatty liver disease and its associated insulin resistance in rats via inhibition of food intake, enhancing hepatic adiponectin signaling, and blocking ghrelin acylation
    Eman F. Khaleel, Ghada A. Abdel‐Aleem · 2018 · Archives of Physiology and Biochemistry
  44. Increased Growth Differentiation Factor 15 in Patients with Hypoleptinemia-Associated Lipodystrophy
    Susan Kralisch, Annett Hoffmann, Juliane Estrada-Kunz, Michael Stümvoll, Mathias Faßhauer, Anke Tönjes, Konstanze Miehle · 2020 · International Journal of Molecular Sciences
  45. Metreleptin for metabolic disorders associated with generalized or partial lipodystrophy
    Vinaya Simha · 2014 · Expert Review of Endocrinology & Metabolism
  46. Chapter 36 – Role of the Adipocyte in Metabolism and Endocrine Function
    E. Ravussin, Steven R. Smith · 2016 · Elsevier eBooks
  47. Syndromic Insulin Resistance: Models for the Therapeutic Basis of the Metabolic Syndrome and Other Targets of Insulin Resistance
    Phillip Görden, Elika Safar Zadeh, Elaine K. Cochran, Rebecca J. Brown · 2012 · Endocrine Practice
  48. Metreleptin Treatment in Three Patients with Generalized Lipodystrophy
    Carla Musso, María Laura Major, Eugenia Andres, Vinaya Simha · 2016 · Clinical Medicine Insights Case Reports
  49. Developmental origins of nonalcoholic fatty liver disease as a risk factor for exaggerated metabolic and cardiovascular-renal disease
    Frank Travis Spradley, Jillian A. Smith, Barbara T. Alexander, Christopher D. Anderson · 2018 · American Journal of Physiology-Endocrinology and Metabolism
  50. Metreleptin for the treatment of lipodystrophy: leading the way among novel therapeutics for this unmet clinical need
    Stergios A. Pοlyzos, Christos Socrates Mantzoros · 2022 · Current Medical Research and Opinion
  51. Adipocytokines in Steatotic Liver Surgery/Transplantation
    Mónica B. Jiménez‐Castro, Araní Casillas-Ramírez, Elsa Negrete-Sánchez, Cindy G. Avalos-de León, Jordi Gracia‐Sancho, Carmen Peralta · 2018 · Transplantation
  52. Benefits of leptin therapy in HIV patients
    Uma Sinha, Keshab Sinharay, Nilanjan Sengupta, Prasanta Mukhopadhyay · 2012 · Indian Journal of Endocrinology and Metabolism
  53. Recent update on pathogenesis of nonalcoholic fatty liver disease
    Joo Hyun Sohn, Tae Yeob Kim · 2010 · The Korean Journal of Internal Medicine
  54. Adipokines in Non-Alcoholic Fatty Liver Disease
    Ancha V. Baranova, Zobair M. Younossi · 2007 · Humana Press eBooks
  55. Hepatobiliary pathology
    Jay H. Lefkowitch · 2006 · Current Opinion in Gastroenterology
  56. Advances in the care of lipodystrophies
    Isabel Shamsudeen, Robert Alexander Hegele · 2021 · Current Opinion in Endocrinology Diabetes and Obesity
  57. Post–Liver Transplant Leptin Results in Resolution of Severe Recurrence of Lipodystrophy-Associated Nonalcoholic Steatohepatitis
    Stephen Casey, Julie Lokan, Adam Testro, Sean Farquharson, Alan Connelly, Joseph Proietto, Peter Angus · 2013 · American Journal of Transplantation
  58. Nonalcoholic Fatty Liver Disease
    Henryk Dancygier · 2009 · Springer eBooks
  59. Hunger & satiety signals: another key mechanism involved in the NAFLD pathway
    I. López-Méndez, Andrea Del Carmen Maldonado-Rojas, Misael Uribe, Eva Juárez-Hernández · 2023 · Frontiers in Endocrinology
  60. Lipodystrophy Severity Score to Assess Disease Burden in Lipodystrophy
    Rebecca J. Brown, Barış Akıncı, Matheos Yosef, Helen Phillips, Shokoufeh H. Khalatbari, Ekaterina Sorkina, Ferruccio Santini, Corinne Vigouroux, Maiah N. Brush, Rasimcan Meral et al. · 2025 · The Journal of Clinical Endocrinology & Metabolism
  61. Leptin and Its Emerging Role in Children and Adolescents
    Iosif Kelesidis, Christos Socrates Mantzoros · 2006 · Clinical Pediatric Endocrinology
  62. Fatty Liver and Autoimmune Hepatitis: Two Forms of Liver Involvement in Lipodystrophies
    Andréia Zanon Lopes Ribeiro, José Ricardo Brandão, Esmeralda Cleto · 2019 · GE Portuguese Journal of Gastroenterology
  63. Clinical Guidance for Lipodystrophy Syndromes: From Diagnosis and Work-Up to Treatment
    Donatella Gilio, Maria Cristina Foss‐Freitas, Elif A Oral · 2025 · Current Diabetes Reports
  64. Pathogenesis of NAFLD and NASH
    Jacquelyn J. Maher · 2015 · Springer eBooks
  65. Adipokines in Nonalcoholic Fatty Liver Disease
    Ancha V. Baranova, Aybike Birerdinc, Zobair M. Younossi · 2014 · Humana Press eBooks
  66. Berardinelli–Seip syndrome: highlight of treatment challenge
    Nélia Ferraria, Cristina Pedrosa, Daniela Amaral, Lurdes Lopes · 2013 · BMJ Case Reports
  67. Metreleptin treatment of non-HIV lipodystrophy syndromes
    Benjamin Chevalier, Madleen Lemaître, Lysiane Leguier, Kristell Le Mapihan, Claire Douillard, Arnaud Jannin, Stéphanie Espiard, Marie‐Christine Vantyghem · 2021 · La Presse Médicale
  68. Lipodystrophy Syndromes
    Michael A. Tsoukas, Christos Socrates Mantzoros · 2015 · Elsevier eBooks
  69. The clinical efficacy of the adipocyte-derived hormone leptin in metabolic dysfunction
    Phillip Görden, Jean Y. Park · 2006 · Archives of Physiology and Biochemistry
  70. Nonalcoholic Fatty Liver Disease
    Curtis Kent Argo, Zachary H. Henry, Stephen Hugh Caldwell · 2017
  71. Protective Effects of Voluntary Exercise on Hepatic Fat Accumulation Induced by Dietary Restriction in Zucker Fatty Rats
    Yuka Kurosaka, Shuichi Machida, Yoko Shiroya, Hideki Yamauchi, Kumiko Minato · 2021 · International Journal of Molecular Sciences
  72. Leptin acutely increases hepatic triglyceride secretion in patients with lipodystrophy
    Marianna Beghini, Matthäus Metz, Clemens Baumgartner, Peter S. Wolf, Magdalena Bastian, Martina Theresa Hackl, Sabina M. Baumgartner-Parzer, Rodrig Marculescu, Michael Krebs, Jürgen Harreiter et al. · 2025 · Metabolism
  73. Pathology of Alcoholic and Nonalcoholic Fatty Liver Disease
    Pierre Bédossa, David Erwin Kleiner · 2015 · Springer eBooks
  74. Genetic Disorders of Insulin Action: Far More than Diabetes
    Benjamin Challis, Robert K. Semple · 2013 · Current Obesity Reports
  75. Non‐Alcoholic Fatty Liver Disease
    Christopher Paul Day · 2010
  76. Nonalcoholic Fatty Liver Disease
    Stephen Hugh Caldwell, Curtis Kent Argo, Abdullah M. S. Al‐Osaimi · 2011
  77. Lipodystrophie-Erkrankungen
    Konstanze Miehle, Julia von Schnurbein, Mathias Faßhauer, Michael Stümvoll, Guntram Borck, Martin Wabitsch · 2017 · Medizinische Genetik
  78. Leptin in the treatment of lipodystrophy-associated nonalcoholic fatty liver disease: are we there already?
    Mariana Verdelho Machado, Helena Cortez‐Pinto · 2013 · Expert Review of Gastroenterology & Hepatology
  79. Monogenic Forms of Diabetes
    Mark A. Sperling, Abhimanyu Garg · 2018 · Europe PMC (PubMed Central)
  80. Adipokine Production by Adipose Tissue: A Novel Target for Treating Metabolic Syndrome and its Sequelae
    Vanessa DeClercq, Danielle M. Defries, Ryan Hunt, Carla G. Taylor, Peter C. Zahradka · 2011 · Wiley eBooks
  81. Lipodystrophic Laminopathies: From Dunnigan Disease to Progeroid Syndromes
    Everardo Josué Díaz‐López, Sofía Sánchez‐Iglesias, Ana I. Castro, Silvia Cobelo-Gómez, Teresa Prado‐Moraña, David Araújo‐Vilar, Antía Fernández‐Pombo · 2024 · International Journal of Molecular Sciences
  82. Metreleptin Treatment in a Boy with Congenital Generalized Lipodystrophy due to Homozygous c.465_468delGACT (p.T156Rfs*8) Mutation in the BSCL2 Gene: Results From the First-year
    Şervan Özalkak, Meliha Demiral, Edip Ünal, Funda Feryal Taş, Hüseyin Önay, Hüseyin Demirbilek, Mehmet Nuri Özbek · 2022 · Journal of Clinical Research in Pediatric Endocrinology
  83. Adipose transplantation improves metabolism and atherosclerosis but not perivascular adipose tissue abnormality or vascular dysfunction in lipodystrophic Seipin/Apoe null mice
    Zhe Meng, Chuangxing Liu, Mengke Xu, Ye-Qing Tao, Haiyu Li, Xijia Wang, Jiawei Liao, Mengyu Wang · 2024 · American Journal of Physiology-Cell Physiology
  84. Efficacy and Safety of Obeticholic Acid for Treating Hepatic Steatosis in Patients With Familial Partial Lipodystrophy
    Abhimanyu Garg, Chandna Vasandani, Xilong Li, Claudia Quittner, Takeshi Yokoo · 2025 · The Journal of Clinical Endocrinology & Metabolism
  85. Low Birth Weight and Insulin Resistance Associated with Lean Body Adiposity in an Adolescent Onset Diabetic Patient
    Naoya Igaki, Maki Tanaka, Takeo Goto · 2006 · Internal Medicine
  86. Decision support system for predicting metabolic risks in patients with comorbid non-alcoholic fatty liver disease and gallstone disease after cholecystectomy
    N. A. Cherkashchenko, Maria A. Livzan, Tatyana S. Krolevets · 2020 · Medical alphabet
  87. Lipodystrophy Syndromes
    Chuanyun Gao, Christos Socrates Mantzoros · 2010 · Elsevier eBooks
  88. Advances of pharmacological therapies in lipodystrophy syndromes: current evidence and future directions
    Özge Besci, Merve Çelik Güler, Maria Cristina Foss‐Freitas, Elif A Oral · 2025 · Expert Review of Endocrinology & Metabolism
  89. Pathogenesis of Hepatic Steatosis and Fibrosis: Role of Leptin
    Faidon Magkos, Elisa Fabbrini, Samuel Klein · 2014 · Springer eBooks
  90. Esteatosis hepática y resistencia a la insulina: ¿qué ocurre primero?
    E. Esteve-Lafuente, Wifredo Ricart · 2006 · Clínica e Investigación en Arteriosclerosis
  91. Nonalcoholic Fatty Liver Disease and Adipokines: A Novel Role for Fat Imbalance
    Stergios A. Pοlyzos · 2013 · ImmunoGastroenterology
  92. The Effect of Phaseolus Angularis Shell on Soyang-in Metabolic Syndrome with Obesity
    Jin-Young Kwak, Jung‐Hwan Park, Young-Mee Koh · 2017 · Journal of Sasang Constitutional Medicine
  93. Lipodystrophies and Dyslipidemias
    Abhimanyu Garg · 2015 · Contemporary Endocrinology
  94. The emerging clinical significance of leptin in humans with absolute or relative leptin deficiency
    Stergios J. Moschos, Christos Socrates Mantzoros · 2005 · Current Opinion in Internal Medicine
  95. Metabolic-Associated Steatotic Liver Disease and FGF21 Dysregulation in Seipin-Deficient and BSCL2-Associated Celia’s Encephalopathy Murine Models
    Silvia Cobelo-Gómez, Lía García-Formoso, Antía Fernández‐Pombo, Héctor Lázare‐Iglesias, Everardo Josué Díaz‐López, Teresa Prado‐Moraña, Laura Rodríguez-Sobrino, Ana Senra, David Araújo‐Vilar, Sofía Sánchez‐Iglesias · 2025 · International Journal of Molecular Sciences
  96. Obesidad y enfermedad hepática
    María E. Miquilena-Colina, Carmelo García Monzón · 2010 · Gastroenterología y Hepatología
  97. Leptin is associated with the size of the apolipoprotein(a) particle in African tribal populations living on fish or vegetarian diet
    Mikołaj Winnicki, Massimo Puato, Virend Kristen Somers · 2010 · Atherosclerosis
  98. Role of the Adipocyte in Metabolism and Endocrine Function
    Éric Ravussin, Steven R. Smith · 2010 · Elsevier eBooks
  99. Correspondence to editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”
    Yitong Li, Weiqing Shao, Zhenmei Chen · 2025 · Clinical and Molecular Hepatology
  100. Clinical Applications of Leptin
    Elif A Oral, Alex M. DePaoli · 2006 · Springer eBooks